Last reviewed · How we verify
IV Ondansetron 4mg
At a glance
| Generic name | IV Ondansetron 4mg |
|---|---|
| Also known as | Pharmacological intervention |
| Sponsor | Dr Lim Siu Min |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase I PK and Safety Study of Ondansetron Inhalation Powder (PHASE1)
- Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (PHASE2, PHASE3)
- Tariquidar-ondansetron Combination in Neuropathic Pain (PHASE1, PHASE2)
- Comparison of Haloperidol and Ondansetron in Reducing Postoperative Nausea and Vomiting in RA-SAB Patients (NA)
- Preventative Effect of Combining Dexamethasone with Ondansetron on Postoperative Nausea, Vomiting and Shivering in Children Undergoing Caudal Anesthesia on Hypospadias Surgery (PHASE4)
- Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (PHASE1)
- Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas (PHASE1, PHASE2)
- Comparison of the Efficacy of Acupressure P6 Point, Dexamethasone and Ondansetron Versus Palonosetron Monotherapy for Preventing Postoperative Nausea and Vomiting in Laparoscopic Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Ondansetron 4mg CI brief — competitive landscape report
- IV Ondansetron 4mg updates RSS · CI watch RSS
- Dr Lim Siu Min portfolio CI